Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study

• Main Authors: Selma Atalay (Author), Juul M.P.A. van den Reek (Author), Marisol E. Otero (Author), Marcellus D. Njoo (Author), Johannes M. Mommers (Author), Paul M. Ossenkoppele (Author), Marjolein I. Koetsier (Author), Maartje M. Berends (Author), Peter C.M. van de Kerkhof (Author), Hans M.M. Groenewoud (Author), Alfons A. den Broeder (Author), Elke M.G.J. de Jong (Author), Wietske Kievit (Author)
• Format: Book
• Published: Medical Journals Sweden, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patients with psoriasis with low disease activity. The a...